Biology subjects

van den Bor, J.

Publications and source records attributed to van den Bor, J..

2 recordsLinked to original sources

bioRxiv2026

Stoichiometry-dependent specificity in biotin enrichment: a benchmarking framework for proximity labeling proteomics

Proximity labeling methods (including, BioID, TurboID, ultraID), along with surface proteomics and microdomain mapping, enable proteome-wide identification of spatially proximal proteins via MS-based analysis. These workflows require specific enrichment of biotinylated proteins using affinity purification, yet enrichment specificity can often be compromised by non-specifically bound proteins. As labeling strategies are increasingly applied to complex biological samples with low protein input or low biotin stoichiometry, accurately distinguishing true targets from background becomes a major analytical challenge. Despite its critical impact on data quality and interpretation, the influence of biotinylation level and protein input on enrichment performance remains poorly characterized, limiting the reliability of proximity labeling experiments. To address this, we establish a quantitative benchmarking framework that systematically evaluates biotin enrichment under controlled conditions, including scenarios of low biotin stoichiometry. Using this setup, we show that enrichment specificity strongly depends on biotin stoichiometry: higher levels of biotinylation in samples yield high specificity, whereas low biotinylation increases non-specific background. Reduced protein input further limits recovery of true targets, yet maintains enrichment specificity, highlighting sensitivity constraints of enrichment-based workflows. We apply this framework to biotinylated extracellular vesicle (EV) cargo uptake in recipient cells using ultraID-CD63 labeling. Detection of the most abundant EV cargo proteins under low biotinylation conditions indicates that current workflows approach the lower bounds of biotin enrichment sensitivity. Together, these standards provide a practical reference for evaluating and optimizing biotin enrichment workflows, supporting quantitative and reproducible proximity labeling in proteomics.

molecular biology↗

bioRxiv2024

Disruption of basal CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms

The chemokine receptor CXCR4 is overexpressed in many cancers and contributes to pathogenesis, disease progression, and resistance to therapies. CXCR4 is known to form oligomers, but the potential functional relevance in malignancies remain elusive. Using a newly established nanobody-based BRET method, we demonstrate that oligomerization of endogenous CXCR4 on lymphoid cancer cell lines correlates with enhanced expression levels. Specific disruption of CXCR4 oligomers reduced basal cell migration and pro-survival signaling via changes in the phosphoproteome, indicating the existence of basal CXCR4-oligomer-mediated signaling. Oligomer disruption also inhibited growth of primary CLL 3D spheroids and sensitized primary malignant cells to clinically used Bcl-2 inhibitor venetoclax. Given its limited efficacy in some patients and the ability to develop resistance, sensitizing malignant B-cells to venetoclax is of clinical relevance. Taken together, we established a new, non-canonical and critical role for CXCR4 oligomers in lymphoid neoplasms and demonstrated that selective targeting thereof has clinical potential. Significance statementClass A GPCRs, including the chemokine receptor CXCR4, can form oligomers, but their functional relevance remains poorly understood. This study provides evidence for the role of basal CXCR4 oligomers in lymphoid neoplasms, where they drive pro-survival signaling, migration, and tumor growth. We use a novel nanobody-based BRET method to demonstrate that endogenous CXCR4 constitutively oligomerizes in lymphoid cancer cells, correlating with receptor expression levels. Pharmacological disruption of these oligomers reduces tumor- associated signaling, impairs spheroid growth, and sensitizes patient-derived malignant cells to the apoptosis-inducing drug Venetoclax. Since CXCR4 is frequently overexpressed and potentially clustered in various malignancies, this work offers broader implications for enhancing treatment efficacy, overcoming drug resistance, and potentially reducing side effects across multiple cancer types.

biochemistry↗